LncRNA HOXA11-AS promotes vascular endothelial cell injury in atherosclerosis by regulating the miR-515-5p/ROCK1 axis

Feng Gao¹, Xiao-Chen Wang¹, Zhi-Dan Luo², Guang-Quan Hu¹, Meng-Qing Ma³, Yi Liang⁴, Bang-Long Xu¹ and Xian-He Lin³*

¹Department of Cardiology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province 230601, China; ²Department of Geriatrics, Chongqing People’s Hospital, Chongqing, China; ³Department of Cardiology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Province 230022, China; and ⁴Houston Methodist Research Institute, Center for Cardiovascular Regeneration, Houston, TX, USA

Abstract

Aims Long non-coding RNA HOXA11-AS participated in heart disease. In this study, we aim to evaluate the potential roles of HOXA11-AS in atherosclerosis and its underlying mechanisms.

Methods and results The expression levels of HOXA11-AS in ox-LDL-treated HUVECs and arch tissues of high-fat diet-fed ApoE⁻/⁻ mice (n = 10) were assessed by qRT-PCR. The effects of HOXA11-AS knockdown on the development of atherosclerosis were evaluated using in vitro and in vivo models. Luciferase reporter and RNA immunoprecipitation (RIP) assays verified the potential relationships between HOXA11-AS or ROCK1 and miR-515-5p. The interactive roles between HOXA11-AS and miR-515-5p and between miR-515-5p and ROCK1 were further characterized in ox-LDL-treated HUVECs. Our data showed that HOXA11-AS was significantly up-regulated (P < 0.001), whereas miR-515-5p was dramatically down-regulated in AS mice tissues (P < 0.001) and ox-LDL-treated HUVECs (P < 0.01). Ox-LDL could induce endothelial injuries by inhibiting cell proliferation (P < 0.001) and SOD synthesis (P < 0.001), promoting apoptosis (P < 0.01), ROS (P < 0.001), and MDA production (P < 0.001), increasing Bax (P < 0.001) and cleaved Caspase-3 (P < 0.001), and decreasing Bcl-2 (P < 0.001) and phosphorylated eNOS (P < 0.01). HOXA11-AS knockdown attenuated endothelial injuries via increasing eNOS phosphorylation. Luciferase assay and RIP results confirmed that miR-515-5p is directly bound to HOXA11-AS and ROCK1. HOXA11-AS promoted ox-LDL-induced HUVECs injury by directly inhibiting miR-515-5p from increasing ROCK1 expression and subsequently decreasing the expression and phosphorylation of eNOS. MiR-515-5p mimics could partially reverse the effects of HOXA11-AS knockdown.

Conclusions HOXA11-AS contributed to atherosclerotic injuries by directly regulating the miR-515-5p/ROCK1 axis. This study provided new evidence that HOXA11-AS might be a candidate for atherosclerosis therapy.

Keywords LncRNA HOXA11-AS; Atherosclerosis; miR-515-5p; ROCK1; Vascular endothelial cell dysfunction

Introduction

Atherosclerosis is a leading blood vessel disease, mainly caused by the inflammatory response, lipid deposition, fibrosis of the arterial wall, and the vulnerable plaques. It can progressively induce the lesion and narrowing of arteries. Increasing evidence confirmed that the low-density lipoprotein cholesterol (LDL) accumulation in endothelial cells is responsible for the development of atherosclerosis. The depositions of lipoproteins can cause the dysfunction and
structural alteration of endothelial cells. After being activated by oxidized lipids and ox-LDL, the endothelial cells could further recruit other inflammatory cells to exacerbate the atherosclerotic injuries. Hence, the endothelial cell was a crucial factor for atherosclerosis. Hence, the study of how ox-LDL influenced endothelial cells and their subsequent responses will provide us with new insights into atherosclerosis therapeutics.

lncRNAs are transcribed RNAs with about 200 nucleotides but no protein-coding function. They participate in transcriptional regulation, post-transcriptional regulation and act as endogenous decoys to control the expression of miRNAs. Further studies showed that lncRNAs could regulate lipid metabolism, inflammatory response, and angiogenesis. Until now, several lncRNAs are closely related to vascular diseases, such as lncRNA GAS5, NORAD, ZEB1-AS, and TUG1. LncRNA HOAX11-AS exhibited a high level in symptomatic atherosclerotic patients. Recently, studies confirmed that HOAX11-AS was closely related to the expressions of inflammation-related genes TNF-α, adipocyte differentiation, and cardiac fibrosis. Mechanically, lncRNAs could bind to miRNA 3’ untranslated regions (3’UTRs) and regulate mRNA transcript during angiogenesis and tumorigenesis. By bioinformatics analysis, we found HOAX11-AS contained a binding sequence for miR-515-5p. Therefore, we wondered whether HOAX11-AS promoted atherosclerosis by directly regulating miR-515-5p.

ROCK1 can regulate cell cytoskeleton organization, adhesion, proliferation, and apoptosis. A series of evidence showed ROCK1 as a downstream effector of TGF-β was actively involved in the pathophysiological events in cardiovascular diseases, such as hypertension, heart failure, and atherosclerosis. Endothelial nitric oxide synthase (eNOS) is a crucial modulator of cardiovascular homeostasis, which is responsible for the production of nitric oxide (NO). The phosphorylation of eNOS could directly regulate the eNOS-mediated NO production. Abnormal synthesis of eNOS and phosphorylation of eNOS contributed to cardiovascular diseases, including atherosclerosis. Previous experiments confirmed that ROCK negatively modulates the activation of eNOS via the inactivation of protein kinase B (PKB). Hence, ROCK1 is an essential target for treating cardiovascular diseases, including atherosclerosis. Intriguingly, the starBase database predicted that ROCK1 had a complementary binding site of miR-515-5p, which helped us hypothesize that the HOAX11-AS/miR-515-5p/ROCK1 pathway might regulate atherosclerosis via influencing the activation of eNOS.

In the current study, we aimed to check the expressions of HOAX11-AS and miR-515-5p in atherosclerotic mice tissues and oxidized LDL-induced HUVEC and further investigate the functions of HOAX11-AS knockdown and miR-515-5p on the progression of atherosclerosis. Mechanistically, we evaluated the relationships among HOAX11-AS, miR-515-5p, and ROCK1 and further characterized the potential mechanisms of HOAX11-AS/miR-515-5p/ROCK1 in atherosclerosis. This study will provide us a new insight to treat atherosclerosis.

Methods

Characteristics of atherosclerotic models in ApoE−/− mice

We purchased thirty 6–8 weeks aged ApoE knockout (ApoE−/−) male mice and ten C57BL/6J mice (bodyweight 20–30 g) from Medical Science Experimental Animal Center (Guangdong, China). Mice were maintained in 5 mice per cage with free access to water and food in an SPF grade laboratory environment (22 ± 2°C and a 12 h day/night cycle). After acclimatization, the ApoE−/− mice were randomly separated into three groups (10 mice per group) and fed a high-fat diet (HFD, Research Diets, New Brunswick, NJ, USA). C57BL/6J mice were fed with a regular chow diet (Lactamin, Stockholm, Sweden). Then, the ApoE−/− mice were injected with sh-NC or sh-HOAX11-AS lentivirus by tail vein (7.5 × 10^7 TU per mice). The sh-NC and sh-HOAX11-AS lentivirus were purchased from Shanghai GenePHarma (Shanghai, China). We sacrificed the mice after 12 weeks following lentivirus injection and high-fat feeding. After sacrifice, we collected blood to isolate the plasma. Then, plasma lipids total cholesterol (TC), triglyceride (TG), high-density lipoprotein, and LDL were measured by ELISA assays using commercial kits (Nanjing Jiancheng Biotech Co., Nanjing, China). The aorta was collected and stored at −80°C for gene expression. The remaining mice were perfused with 4% paraformaldehyde in 1 × pre-cold PBS for immunostaining assays. The Ethics Committee of The First Affiliated Hospital of Anhui Medical University approved all the above-mentioned experimental procedures.

Cell transfection

Human Umbilical Vein Endothelial Cell (HUVEC, Thermo Fisher Scientific, Shanghai, China) was grown in Medium 200 with low serum supplement (LSGS, cat. no. S-003-10) 37°C in a humidified incubator. We purchased 1 × 10^8 TU/mL pGPU6-GFP-Neo-HOAX11-AS (sh-HOAX11-AS) and the empty vector pGPU6-GFP-Neo, miR-515-5p mimics/inhibitor, and the corresponding negative or positive mimics control, pcDNA3.1-ROCK1, and pcDNA3.1 empty vector from Guangzhou RiboBio Co., Ltd, China. For HUVECs transfection, we transfected cells with sh-HOAX11-AS lentivirus, miR-515-5p.
mimics/inhibitors, pcDNA3.1-ROCK1, or the corresponding control by Invitrogen Lipofectamine 2000 (Fisher Scientific, MA, USA). The characteristics of sh-HOXA11-AS lentiviral vector were shown in supporting information, Data S1. qRT-PCR confirmed the effectiveness of transfection.

**MTT assay**

CyQUANT™ MTT Cell Proliferation Assay Kit (V13154) was bought from Invitrogen, USA. The 1 × 10^3 HUVECs cells were plated into each well of 96-well plates. Subsequently, cells were incubated with 0, 20, 40, 60, 80 μg/mL ox-LDL (Sigma-Aldrich, MO, USA) for 24 h. Then, 5 mg/mL of MTT reagent (Sigma-Aldrich, MO, USA) was added and incubated for a further 4 h at 37°C. After being dissolved by 0.01 M HCl-SDS solution, the dissolved formazan was measured at 570 nm using a Thermomax microplate reader (BioTek EL, Vermont, USA).

**Flow cytometry**

The HUVECs were collected after treatment and stained with AnnexinV-FITC/propidium iodide (PI) (Sigma-Aldrich, MO, USA). Cells were detected by Cytomics FC500 Flow Cytometer (Beckman Coulter, CA, USA). The ratio of the apoptotic cells to total cells was calculated.

**Dual-luciferase reporting assay**

We purchased pGL3 vectors containing the wide-type and mutant binding sequences of miR-515-5p in HOXA11-AS and ROCK1 from Guangzhou RiboBio Co., Ltd, China (Guangdong, China). They are named as pGL3-HOXA11-AS wide-type (HOXA11-AS WT), pGL3-HOXA11-AS mutant (HOXA11-AS MUT), pGL3-ROCK1 wide-type (ROCK1 WT), and pGL3-ROCK1 mutant (ROCK1 MUT).

HUVECs were transfected with the indicated luciferase vector single or cotransfected with mimics NC or miR-515-5p mimics using Lipofectamine 2000 (Thermo Fisher Scientific, USA). The luciferase activities were measured 48 h after transfection using a commercial kit (Promega, Madison, USA). The Renilla luciferase acted as an internal control.

**RIP**

Whole HUVECs extracts were obtained and reacted with magnetic beads conjugated with human anti-Ago2 antibody (MilliporeSigma, MA, USA) or negative control IgG (MilliporeSigma). After the antibody was recovered using protein A/G beads, the bounded RNAs were eluted by Trizol (Thermo Fisher Scientific, USA). qRT-PCR was performed to measure the levels of HOXA11-AS and miR-515-5p.

**Haematoxylin and eosin staining**

The aortic arch to the branch of the abdominal aorta was dissected and immersed in precooled 4% paraformaldehyde (PFA, Sigma-Aldrich) in PBS at 4°C overnight. After a brief wash with 1 × phosphate-buffered saline, the aortic arch was processed directly for paraffin embedding and microtome sectioned at thickness 5 nm by a microtome (HistoCore BIOCUT, Leica, USA) according to the previous method. After serial dewax and rehydration, the sections were stained by haematoxylin solution (Sigma-Aldrich) for 5–10 min. After being rinsed under tap water, the tissues were differentiated using 1% aqueous hydrochloric acid, and the development of staining was checked under a microscope. After rinsing for 5 min in running tap water, the sections were counterstained by eosin alcoholic solution for 0.5–1 min. Finally, the sections were dehydrated by increasing serial concentration of ethanol (70%, 90%, and 100% ethanol, each for 2 min) and cleared in xylene for 2 min. After mounting with neutral resin, the sections were imaged under a microscope with a camera. Two independent pathologies evaluated the lesions in a blinded manner.

**Measurement of ROS, MDA, and SOD**

The HUVECs were transfected by a sh-NC, sh-HOXA11-AS single, or together with inhibitor NC, miR-515-5p inhibitor. Twenty-four hours later, 80 μg/mL ox-LDL was added into cells and incubated for a further 24 h. Subsequently, HUVECs were incubated with 10 μM of ROS-sensitive substrate CM-H2DCFDA (Beyotime Biotechnology, Shanghai, China) for 20 min and measured by flow cytometry. A commercial MDA ELISA kit was used to determine MDA and SOD production (Beyotime Biotechnology, Shanghai, China).

**Measurement of blood lipid**

After collecting blood from each mouse, the blood triglyceride (TG), total cholesterol (TC), and LDL-C levels in the sera were detected using the corresponding commercial kits (Abcam, CA, USA) according to the protocols.

**Quantitative real-time PCR**

Total RNA was isolated using a Qiagen RNeasy Mini Kit (Fisher Scientific). A PrimeScript RT Reagent Kit was used to reversely transcribe 1 μg of total RNA into cDNA.
(TaKaRa, Dalian, China). The expressions of HOXA11-AS and ROCK1 were detected by the SYBR Green Master Mix kit (Takara). MiR-515-5p expression was detected by TaqMan™ MicroRNA Assay (Thermo Fisher Scientific). β-actin and U6 were the corresponding internal control. qRT-PCR procedures were performed on the Rotor-Gene Q (Qiagen). The 2−ΔΔct method was used to analyse relative expression. The primer sequences were listed below:

HOXA11-AS, F: 5′-CAGGTCGAGGTCTTTGCGGATG-3′, R: 5′-CAGAAA-3′

miR-515-5p, F: 5′-CGTACAGGTCTTTGCGGATG-3′, R: 5′-GTTTAGCACGCAATTGCTCA-3′

ROCK1, F: 5′-CAATTTGCTTTGCGGATG-3′, R: 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTGAC-3′

GGCTCTGGGTTGACGATAAA-3′

The concentrations were quantified using RIPA buffer with 1 mM PMSF. After preclear by centrifuge, the samples were applied to 10% SDS-PAGE and were transferred to PVDF membranes (Millipore, Billerica, MA, USA). Then, 10 μg of total protein was separated by 10% SDS-PAGE and was transferred onto a PVDF membrane (Millipore, Billerica, MA, USA). After 1 h blocking by 5% BSA in TBST (Sigma-Aldrich, USA), the membranes were incubated with primary antibodies in a cold room on a rotator. The primary antibodies are mouse anti-β-actin (ab182733, Abcam, 1:2000), rabbit anti-p-eNOS (ab215717, Abcam, 1:2000), and rabbit anti-eNOS (ab199956, Abcam, 1:2000). After incubation with secondary antibodies, the membranes were developed by Pierce™ ECL (Thermo Fisher Scientific, USA). Image Lab™ 4.1 (Bio-Rad, USA) took and quantified the images.

Results

HOXA11-AS was up-regulated in atherosclerosis

Our data showed that HOXA11-AS was remarkably up-regulated in atherosclerosis mice aortic plaque tissue compared with the control group (Figure 1A). As shown in Figure 1B, ox-LDL caused a dose-dependent decrease in cell viability. The relative expression of HOXA11-AS was dramatically increased in a dose-dependent manner (Figure 1C). These results indicated that HOXA11-AS was up-regulated in atherosclerosis.

HOXA11-AS silencing diminished ox-LDL induced injury in HUVECs

Our data indicated HOXA11-AS expression was significantly inhibited after the transfection of sh-HOXA11-AS compared with vehicle control and sh-NC (Figure 2A). Meanwhile, knockdown of HOXA11-AS could attenuate the ox-LDL-induced high level of HOXA11-AS (Figure 2B). Further experiments showed HOXA11-AS silencing could remarkably alleviate the ox-LDL-induced cell proliferation inhibition (Figure 2C) and cell apoptosis promotion (Figure 2D). Compared with sh-NC, we found HOXA11-AS knockdown markedly suppressed the ox-LDL-induced production of ROS (Figure 2E) and Malondialdehyde (MDA) (Figure 2F). The further experiment identified that HOXA11-AS knockdown reversed ox-LDL-induced low level of Superoxide dismutase (SOD) (Fig. 2G). HOXA11-AS knockdown could lead to distinct up-regulation of anti-apoptotic Bcl-2 protein and apparent down-regulation of pro-apoptotic Bax and cleaved-caspase-3 proteins (Figure 2H). However, compared with the control, knockdown of HOXA11-AS could antagonize the inhibitory effects of ox-LDL on the phosphorylation of eNOS rather than the total eNOS (Figure 2I). Those results revealed that HOXA11-AS silencing alleviated ox-LDL-induced injuries in HUVECs, possibly through increasing the phosphorylation of eNOS.

Knockdown HOXA11-AS alleviated atherosclerosis in ApoE−/− mice

To silence the HOXA11-AS gene in atherosclerosis, we injected lentivirus sh-HOXA11-AS or sh-NC to ApoE−/− mice. Then, ApoE−/− mice were administered a 10 week high-fat diet to develop the atherosclerosis model. After sacrifice, the relative HOXA11-AS levels in the aortic arch tissue of the control or HFD-fed ApoE−/− mice. When HOXA11-AS was knockdown in AS mice through the injection of sh-HOAX11-AS lentivirus, our result revealed that knockdown of HOAS11-AS could significantly inhibit the expression of HOAX11-AS in AS mice (Figure 3A).

Statistical analysis

All the results were expressed as means ± SD and performed by Student’s t-test or one-way ANOVA to compare the multiple groups by SPSS. We conducted three separate experiments. *P < 0.05, **P < 0.01. P < 0.05 was considered as statistical significance.
The eosin staining assay showed that atherosclerosis mice’s aortic arch tissue exhibited the thickened aortic arch vascular wall, the increased accumulation of foam cells, the ruptured vascular wall, and the atherosclerotic lesion in the aortic arch (Figure 3B). In contrast, we did not find the atherosclerotic lesion in the aortic arch of the normal mice (Figure 3B). By silencing HOXA11-AS, we found a significant decrease in TC, TG, and LDL-c concentrations (Figure 3C–3E) but enhanced the phosphorylation of eNOS rather than the total eNOS in the aortic arch tissues of AS mice (Figure 3F). Those data confirmed inhibition of HOXA11-AS protected mice from atherosclerotic injury.

**HOXA11-AS inhibited miR-515-5p expression**

The bioinformatics analysis indicated miR-515-5p contained a putative binding site for HOXA11-AS (Figure 4A). So we wondered whether miR-515-5p was altered in atherosclerosis. Using the normal and atherosclerosis aortic tissues, we checked miR-515-5p expression and found it reduced in the atherosclerosis aortic arch (Figure 4B). Then, we measured the miR-515-5p expression in ox-LDL-induced HUVECs. Interestingly, we observed a significant reduction in miR-515-5p expression in a dose-dependent manner (Figure 4C). However, in contrast with the effect of sh-NC transfection, HOXA11-AS knockdown reversed miR-515-5p (Figure 4D). Next, we performed a luciferase assay to investigate their regulation. After transfection of miR-515-5p mimics, we found the level of miR-515-5p was significantly enhanced, miR-515-5p inhibitor dramatically inhibited miR-515-5p expression (Figure 4E). Then, we transfected WT and MUT HOXA11-AS luciferase reporter vector with mimic NC or miR-515-5p mimics. The results indicated that miR-515-5p mimics decreased the luciferase activity compared to the mimics NC group, but no significant change was observed on the luciferase activity in the HOXA11-AS-MUT reporter (Figure 4F). Subsequent RIP assay further confirmed their relationship (Figure 4G). The results showed that both HOXA11-AS and miR-515-5p were highly enriched by anti-Ago2 compared with anti-IgG, indicating HOXA11-AS had the endogenous interaction with miR-515-5p.

**HOXA11-AS exacerbated ox-LDL-induced HUVECs injuries by inhibiting miR-515-5p**

Our data revealed that miR-515-5p inhibition by transfection of miR-515-5p inhibitor significantly suppressed the increased cell proliferation (Figure 5A) and promoted cell apoptosis (Figure 5B). Functionally, silencing of HOXA11-AS remarkably inhibited ROS and Malondialdehyde (MDA) and promoted Superoxide dismutase (SOD) synthesis, but a miR-515-5p inhibitor overturned the effects (Figure 5C–5E). Further experiments showed silencing of HOXA11-AS distinctly increased cell viability and inhibited cell apoptosis, as showed by the increased Bcl-2 and the decreased Bax and cleaved caspase-3, whereas miR-515-5p inhibition abolished the effects (Figure 5F). Knockdown of HOXA11-AS could induce remarkably increased phosphorylated eNOS in ox-LDL-treated HUVECs, but knockdown of HOAX11-AS could enhance the expression of phosphorylated eNOS. However, inhibition of miR-515-5p could significantly attenuate the increased expression of phosphorylated eNOS by knockdown of HOXA11-AS in ox-LDL-treated HUVECs (Figure 5F). These data pointed out that HOXA11-AS regulated atherosclerosis, possibly via controlling the expression of miR-515-5p.

**miR-515-5p directly inhibited ROCK1**

To elucidate the mechanism of miR-515-5p in HOXA11-AS-mediated atherosclerosis, we screened out that the 3’ UTR of ROCK1 contained the binding sequence by StarBase (Figure 6A). Western blot assay showed that atherosclerosis enhanced ROCK1 expression in aortic tissues compared with the control group (Figure 6B). Further experiments indicated that ROCK1 expression gradually increased in ox-LDL-induced HUVECs (Figure 6C). Additional experiments showed that knockdown of HOXA11-AS could remarkably attenuate...
the increased ROCK1 protein levels in AS aortic tissue (Figure 6D) or ox-LDL-induced HUVECs (Figure 6D). miR-515-5p mimics decreased ROCK1 expression, but the miR-515-5p inhibitor positively increased ROCK1 expression (Figure 6F). Additionally, miR-515-5p mimics markedly reduced the luciferase activity of ROCK1-WT reporter, but no significant change was found in mimics NC or miR-515-5p mimics groups (Figure 6G). After transfection of ROCK1 overexpression vector (pcDNA3.1-ROCK1), our qRT-PCR result showed that the pcDNA3.1-ROCK1 transfection highly up-regulated ROCK1 expression rather than vehicle control and pcDNA3.1 empty vector (Figure 6H).

**miR-515-5p antagonized ox-LDL-induced injuries in HUVECs by directly suppressing ROCK1**

To clarify whether miR-515-5p was via regulating ROCK1 to suppress ox-LDL-induced injuries, we transfected HUVECs with miR-515-5p mimics plus pcDNA3.1-ROCK1, followed by...
ox-LDL treatments. Our result indicated that ROCK1 overexpression could diminish the increased cell proliferation (Figure 7A) and the decreased cell apoptosis (Figure 7B) induced by miR-515-5p. Furthermore, miR-515-5p overexpression decreased the production of ROS and Malondialdehyde (MDA) and increased Superoxide dismutase (SOD) synthesis. However, ROCK1 overexpression could reverse the effects induced by miR-515-5p mimics (Figure 7C–7E). When cotransfection of miR-515-5p mimics with pcDNA3.1-ROCK1, ROCK1 overexpression increased Bax and cleaved caspase-3 levels and suppressed the Bcl-2 (Figure 7F). However, ROCK1 overexpression could antagonize the promoting effects of miR-515-5p mimics. Taken together, miR-515-5p protected ox-LDL-induced injury by directly suppressing ROCK1.

**Discussion**

Atherosclerosis is a chronic progressive arterial vascular disease and a leading cause of vascular death.22 Many risk factors such as lipid infiltration, injury-response, and endothelial injuries contributed to the pathogenesis of atherosclerosis.23 Oxidized cholesterol in the diet, particularly ox-LDL, were believed as the primary source of oxidized lipoproteins, which could accelerate the pathogenesis of atherosclerosis.24 After oxidation, ox-LDL stimulates foam cells, induces endothelial dysfunction, plaque formation,
HOXA11-AS was overexpressed in both atherosclerosis mice aortic tissue and ox-LDL-stimulated HUVECs. As mice subjected to the injection of sh-HOXA11-AS lentivirus exhibited significantly decreased expression of HOXA11-AS compared with that of control. Meanwhile, the down-regulation of HOXA11-AS could attenuate ox-LDL-induced injuries, possibly
through the increased eNOS activity in both HUVECs and atherosclerosis mice. The further experiment confirmed that miR-515-5p was a direct target of HOXA11-AS, and ROCK1 was a direct target of miR-515-5p. Additional in vitro and in vivo experiments revealed that knockdown of HOAX11-AS protected endothelial cells from AS via up-regulating miR-515-5p and down-regulating ROCK1. The experiments disclosed that HOXA11-AS promoted atherosclerosis, possibly via regulating the miR-515-5p/ROCK1 axis.

A previous report pointed out that lncRNAs could regulate atherosclerosis events by influencing endothelial cells and macrophages. High-level lncRNA H19 expression induced cell proliferation and caused apoptosis inhibition through up-regulating p38 MAPK and p65 NF-κB. Another report indicated that patients with atherosclerosis exhibited increased LncRNA LOXL1-AS1 expression with the activated miR-515-5p/STAT3 axis. Recently, lncRNA HOXA11-AS was a significant cause of cardiac fibrogenesis by the up-regulation...
The above-mentioned reports highlighted that HOXA11-AS might be a potential candidate for heart diseases. Using the bioinformatics method, we found HOXA11-AS had a putative binding sequence of miR-515-5p. Therefore, we wondered whether HOXA11-AS participated in the atherosclerosis development by regulating miR-515-5p. Here, our experiments confirmed that HOXA11-AS was up-regulated in the aortic tissue of HFD-fed atherosclerosis mice and ox-LDL-induced HUVECs. Meanwhile, knockdown of HOXA11-AS could significantly alleviate ox-LDL-induced inhibitory effect on cell proliferation and diminished cell apoptosis of HUVECs.

Additionally, HOXA11-AS knockdown could attenuate the ROS and MDA releases, increase the expression of SOD, and remarkably inhibit ox-LDL-induced overexpression of Bax and cleaved caspase-3, decreasing Bcl-2. Further in vivo experiments indicated that HOXA11-AS knockdown attenuated the severity of atherosclerosis by the decreased thickness of the vascular wall, the less foam cell accumulation, and vascular ruptures. Meanwhile, the blood lipids TC, TG, LDL-c were also decreased. The life-threaten risk of atherosclerosis is closely related to plaque formation. Although the plaque formation is multifaceted, the lipoprotein-driven inflammation was the initiator of atherosclerosis. High LDL levels, particu-
larly its derivate ox-LDL, are modulators of the immune response, which further induced endothelial cells and SMCs to express the adhesion molecules, growth factors, and chemoattractants. Those inflammatory responses further recruit macrophages and dendritic cells to deposit lipids and become foam cells. Our results indicated that AS accumulated macrophages and lipids but decreased smooth muscle cells and collagens. However, knockdown of HOXA11-AS could significantly inhibit the accumulation of macrophages in the internal membrane of blood vessels and the subsequent generation of foam cells. All these data indicated that HOXA11-AS knockdown had a protective role during atherosclerosis progress.

During the past decade, miRNAs have been identified as significant regulators of atherosclerosis by regulating genes involved with atherosclerosis and modifying their post-transcriptional modification. A recent study confirmed that lncRNAs could regulate the miRNAs. The experiment showed LOXL1-AS1 directly sponged miR-515-5p and subsequently inhibited the expression of STAT3.27 We identified...
that miR-515-5p is directly bound to lncRNA HOXA11-AS and ROCK1. One of the significant causes of atherosclerotic plaques is endothelial dysfunction. Further study showed that atherogenesis is due to abnormal activation of the ROCK pathway. The experiment confirmed that the abnormal active ROCK1 could inhibit eNOS phosphorylation and NO production, which contributed to the dysfunction of endothelial cells. Several miRNAs, such as miR-101-3p and miR-124-3p, could regulate the expression of ROCK1. We used luciferase reporter, and RIP assays further found miR-515-5p directly bound to HOXA11-AS. Additionally, knockdown of HOXA11-AS could diminish ox-LDL-induced inhibition of miR-515-5p. Additionally, inhibition of miR-515-5p could reverse the inhibition of cell apoptosis, the promotion of cell proliferation, the decreased production of ROS and MDA as well as the increased Bcl-2 expression by HOXA11-AS silencing. Furthermore, we also found ROCK1 was overexpressed in atherosclerosis compared with control. ROCK1 overexpression could reverse miR-515-5p-induced increased cell proliferation and SOD synthesis and decreased cell apoptosis, ROS, and MDA productions. Therefore, the down-regulation of HOXA11-AS could influence the progress of atherosclerosis by up-regulating miR-515-5p and inactivating the ROCK1 signalling pathway.

HOXA11-AS has significantly up-regulated in atherosclerosis mice aortic tissues and ox-LDL-induced HUVECs. In this article, we first validated that HOXA11-AS promoted the progress of atherosclerosis via regulating the miR-515-5p/ROCK1 axis. Therefore, the knockdown of HOXA11-AS might be a candidate target to treat atherosclerosis. Because it lacks clinical data, additional evaluation of HOXA11-AS, miR-515-5p, and ROCK1 in atherosclerosis is being carried out in patient samples.

**Acknowledgements**

We would like to give our sincere gratitude to the reviewers for their constructive comments.

**Conflict of interest**

The authors declare that there is no conflict of interest.

**Funding**

This work was supported by grants from projects funded by An-hui Natural Fund General Project (2008085MH239) and (1508085MH145).

**Supporting information**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Data S1.** Supporting information.

---

**References**

1. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. *Nat Med* 2011; **17**: 1410–1422.
2. Howe KL, Fish JE. Transforming endothelial cells in atherosclerosis. *Nat Metab* 2019; **1**: 856–857.
3. Meng Q, Pu L, Luo X, Wang B, Li F, Liu B. Regulatory roles of related long non-coding RNAs in the process of atherosclerosis. *Front Physiol* 2020; **11**: 564604.
4. Yao RW, Wang Y, Chen LL. Cellular functions of long non-coding RNAs. *Nat Cell Biol* 2019; **21**: 542–551.
5. Bian W, Jing X, Yang Z, Shi Z, Chen R, Xu A, Wang N, Jiang J, Yang C, Zhang D, Li L, Wang H, Wang J, Sun Y, Zhang C. Down-regulation of lncRNA NORAD promotes ox-LDL-induced vascular endothelial cell injury and atherosclerosis. *Aging (Albany NY)* 2020; **12**: 6385–6400.
6. Xu X, Ma C, Duan Z, Du Y, Liu C. LncRNA ZEB1-AS1 mediates oxidative low-density lipoprotein-mediated endothelial cells injury by post-transcriptional stabilization of NOD2. *Front Pharmacol* 2019; **10**: 397.
7. Wu X, Zheng X, Cheng J, Zhang K, Ma C. LncRNA TUG1 regulates proliferation and apoptosis by regulating miR-145b/IGF2 axis in ox-LDL-stimulated VSMC and HUVEC. *Life Sci* 2020; **243**: 117287.
8. Jin QS, Huang LJ, Zhao TT, Yao XY, Lin LY, Teng YQ, Kim SH, Nam MS, Zhang LY, Jin YJ. HOXA11-AS regulates diabetic arteriosclerosis-related inflammation via PI3K/AKT pathway. *Eur Rev Med Pharmacol Sci* 2018; **22**: 6912–6921.
9. Nuermaimaiti N, Liu J, Liang X, Jiao Y, Zhang D, Liu L, Meng X, Guan Y. Effect of lncRNA HOXA11-AS1 on adipocyte differentiation in human adipose-derived stem cells. *Biochem Biophys Res Commun* 2018; **495**: 1878–1884.
10. Wang J, Liu X, Zhuang Q, Pan R, Zou L, Cen Z, Tang L. Long non-coding RNA homebox A11 antisense promotes transforming growth factor β1-induced fibrogenesis in cardiac fibroblasts. *Mol Med Rep* 2019; **19**: 2817–2824.
11. López-Urrutia EBML, de Guevara L, Cervantes D, Pérez-Plasencia C, Campos-Parrá AD. Crosstalk between long non-coding RNAs, micro-RNAs and mRNAs: deciphering molecular mechanisms of master regulators in cancer. *Front Oncol* 2019; **9**: 669.
12. Tang H, Zhu M, Zhao G, Fu W, Shi Z, Ding Y, Tang X, Guo D. Loss of CLOCK under high glucose upregulates ROCK1-mediated endothelial to mesenchymal transition and aggravates plaque vulnerability. *Atherosclerosis* 2018; **275**: 58–67.
13. Sunamura S, Satoh K, Kurosawa R, Ohtsuki T, Kikuchi N, Elias-Al-Mamun M et al. Different roles of myocardial...
ROCK1 and ROCK2 in cardiac dysfunction and postcapillary pulmonary hypertension in mice. Proc Natl Acad Sci U S A 2018; 115: E7129–E7138.

14. Zhang YM, Bo J, Taffet GE, Chang J, Shi J, Reddy AK, Michael LH, Schneider MD, Entman ML, Schwartz RJ, Wei L. Targeted depletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. PASEB J 2006; 20: 916–925.

15. Su Q, Zhang P, Yu D, Wu Z, Li D, Shen F, Lao P, Yin G. Upregulation of miR-93 and inhibition of LIMK1 improve ventricular remodeling and alleviate cardiac dysfunction in rats with chronic heart failure by inhibiting RhoA/ROCK signaling pathway activation. Aging (Albany NY) 2019; 11: 7570–7586.

16. Bu DX, Rai V, Shen X, Rosario R, Lu Y, D’Agati V, Yan SF, Friedman RA, Nugaliez E, Schmidt AM. Activation of the ROCK1 branch of the transforming growth factor-beta pathway contributes to RAGE-dependent acceleration of atherosclerosis in diabetic ApoE-null mice. Circ Res 2010; 106: 1040–1051.

17. Ming XF, Viswambharan H, Barandier C, Ruffieux J, Kaibuchi K, Rusconi S, Yang Z. Rho GTPase/Rho kinase negatively regulates endothelial nitric oxide synthase phosphorylation through the inhibition of protein kinase B/Akt in human endothelial cells. Mol Cell Biol 2002; 22: 8467–8477.

18. Chen CA, Druhan LJ, Varadharaj S, Chen YR, Zweier JL. Phosphorylation of endothelial nitric-oxide synthase regulates superoxide generation from the enzyme. J Biol Chem 2008; 283: 27038–27047.

19. Hong FF, Liang XY, Liu W, Lv S, He SJ, Kuang HB, Yang SL. Roles of eNOS in atherosclerosis treatment. Inflamm Res 2019; 68: 429–441.

20. Liu B, Zhang JY, Gao HM, Wang Q, Wang HB. Effect of rosuvastatin on ROCK activity, endothelial function, and inflammation in Asian patients with atherosclerosis. Intern Med 2012; 51: 1177–1182.

21. Andres-Manzano MJ, Andres V, Dorado B. Oil red O and hematoxylin and eosin staining for quantification of atherosclerosis burden in mouse aorta and aortic root. Methods Mol Biol 2015; 1339: 85–99.

22. Herrington W, Lacey B, Sherliker P, Calman KE, Michael LH, Schneider MD, Entman ML, Muster K, Schwartz RJ, Bo J. Targeted deletion of ROCK1 protects the heart against pressure overload by inhibiting reactive fibrosis. Proc Natl Acad Sci U S A 2018; 115: E7129–E7138.

23. Kobiyama K, Ley K. Atherosclerosis. Circ Res 2010; 118: 620–636.

24. Yao L, Romero MJ, Toque HA, Yang G, Caldwell RB, Caldwell RW. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res 2010; 1: 165–170.

25. Deng R, Zhang J, Chen J. IncRNA SNHG1 negatively regulates miRNA103p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma. Int J Mol Med 2019; 43: 1157–1166.

26. Pan JX. LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-kB signaling pathway. Eur Rev Med Pharmacol Sci 2017; 21: 322–328.

27. Xie Q, Li F, Shen K, Luo C, Song G. LOXL1-AS1/miR-515-5p/STAT3 positive feedback loop facilitates cell proliferation and migration in atherosclerosis. J Cardiovasc Pharmacol 2020; 76: 151–158.

28. Bentzon JF, Otsuka F, Vranic M, Fark E. Mechanisms of plaque formation and rupture. Circ Res 2014; 114: 1852–1866.

29. Lu Y, Thavarajah T, Wu W, Cai J, Xu Q. Impact of miRNA in atherosclerosis. Arterioscler Thromb Vasc Biol 2018; 38: e159–e170.

30. Ahadi A, Brennan S, Kennedy PJ, Huttanag G, Tran N. Long non-coding RNAs harboring miRNA seed regions are enriched in prostate cancer exosomes. Sci Rep 2016; 6: 24922.

31. Gimbrone MA Jr, Garcia-Cardenas G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ Res 2016; 118: 620–636.

32. Bentzon JF, Otsuka F, Virmani R, Falk E. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res 2010; 1: 165–170.

33. Deng R, Zhang J, Chen J. IncRNA SNHG1 negatively regulates miRNA103p to enhance the expression of ROCK1 and promote cell proliferation, migration and invasion in osteosarcoma. Int J Mol Med 2019; 43: 1157–1166.

34. Gao C, Shen J, Meng ZX, He XF. Sevoflurane inhibits glioma cells proliferation and metastasis through miRNA-124a-3p/ROCK1 Axis. Pathol Oncol Res 2020; 26: 947–954.